INCB059872

· Incyte Corporation

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for INCB059872, covering 2023-06-12 to 2025-10-21. Get the full timeline:

Most recent: Clinical Trial Update: A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma [Phase 1]